Entry inhibitors and future treatment of hepatitis C

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 136-142

  Fofana, Isabel ^a,b   Jilg, Nikolaus ^c   Chung, Raymond T ^c   Baumert, Thomas F ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Difficult to treat patients; Direct acting antivirals; Entry inhibitors; Liver transplantation; Resistance

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; BOCEPREVIR; CHLOROQUINE; DACLATASVIR; ERLOTINIB; EZETIMIBE; HCV ENTRY INHIBITOR; IBALIZUMAB; IMIDAZOLE; ITX 5061; MARAVIROC; MERICITABINE; PEGINTERFERON ALPHA; RIBAVIRIN; SILYMARIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; DRUG SAFETY; GRAFT INFECTION; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER GRAFT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

DIFFICULT-TO-TREAT PATIENTS; DIRECT-ACTING ANTIVIRALS; ENTRY INHIBITORS; LIVER TRANSPLANTATION; RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; VIRUS INTERNALIZATION;

EID: 84896717972     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.001     Document Type: Note

References (115)

1. D. Bankwitz, E. Steinmann, J. Bitzegeio, S. Ciesek, M. Friesland, E. Herrmann, M.B. Zeisel, T.F. Baumert, Z.Y. Keck, S.K. Foung, E.I. Pecheur, and T. Pietschmann Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes J. Virol. 84 2010 5751 5763
2. E. Bardou-Jacquet, R. Lorho, and D. Guyader Kinase inhibitors in the treatment of chronic hepatitis C virus Gut 60 2011 879 880
3. H. Barth, C. Schäfer, M.I. Adah, F. Zhang, R.J. Linhardt, H. Toyoda, A. Kinoshita-Toyoda, T. Toida, T.H. Van Kuppevelt, E. Depla, F.V. Weizsäcker, H.E. Blum, and T.F. Baumert Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate J. Biol. Chem. 278 2003 41003 41012 (Pubitemid 37280923)
4. B. Bartosch, J. Dubuisson, and F.L. Cosset Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes J. Exp. Med. 197 2003 633 642 (Pubitemid 36314658)
5. K.D. Bissig, S.F. Wieland, P. Tran, M. Isogawa, T.T. Le, F.V. Chisari, and I.M. Verma Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment J. Clin. Invest. 120 2010 924 930
6. E. Blanchard, S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C. Wychowski, and Y. Rouille Hepatitis C virus entry depends on clathrin-mediated endocytosis J. Virol. 80 2006 6964 6972 (Pubitemid 44025195)
7. K.J. Blight, A.A. Kolykhalov, and C.M. Rice Efficient initiation of HCV RNA replication in cell culture Science 290 2000 1972 1975
8. Y.S. Boriskin, E.I. Pecheur, and S.J. Polyak Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection Virol. J. 3 2006 56
9. Y.S. Boriskin, I.A. Leneva, E.I. Pecheur, and S.J. Polyak Arbidol: a broad-spectrum antiviral compound that blocks viral fusion Curr. Med. Chem. 15 2008 997 1005 (Pubitemid 351736402)
10. C.L. Brimacombe, J. Grove, L.W. Meredith, K. Hu, A.J. Syder, M.V. Flores, J.M. Timpe, S.E. Krieger, T.F. Baumert, T.L. Tellinghuisen, F. Wong-Staal, P. Balfe, and J.A. McKeating Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission J. Virol. 85 2011 596 605
11. N. Calland, A. Albecka, S. Belouzard, C. Wychowski, G. Duverlie, V. Descamps, D. Hober, J. Dubuisson, Y. Rouille, and K. Seron (-)-Epigallocatechin- 3-gallate is a new inhibitor of hepatitis C virus entry Hepatology 55 2012 720 729
12. M.T. Catanese, J. Loureiro, C.T. Jones, M. Dorner, T. von Hahn, and C.M. Rice Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission J. Virol. 87 2013 8282 8293
13. M.R. Charlton, E.J. Gane, M.P. Manns, R.S. Brown, M.P. Curry, P.Y. Kwo, R.J. Fontana, R. Gilroy, L.W. Teperman, A.J. Muir, J.G. McHutchison, W.T. Symonds, J.M. Denning, L. McNair, S. Arterburn, N. Terrault, D. Samuel, and X. Forns Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection after Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study 2013 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 3012) Washington [1-5, Abstract LB-2]
14. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, H. Ishikawa, H. Watanabe, F. McPhee, E. Hughes, and H. Kumada Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
15. R.T. Chung, F.D. Gordon, M.P. Curry, T.D. Schiano, S. Emre, K. Corey, J.F. Markmann, M. Hertl, J.J. Pomposelli, E.A. Pomfret, S. Florman, M. Schilsky, T.J. Broering, R.W. Finberg, G. Szabo, P.D. Zamore, U. Khettry, G.J. Babcock, D.M. Ambrosino, B. Leav, M. Leney, H.L. Smith, and D.C. Molrine Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study Am. J. Transplant. 13 2013 1047 1054
16. S. Ciesek, and H. Wedemeyer Immunosuppression, liver injury and post-transplant HCV recurrence J. Viral Hepat. 19 2012 1 8
17. S. Ciesek, S. Westhaus, M. Wicht, I. Wappler, S. Henschen, C. Sarrazin, N. Hamdi, A.I. Abdelaziz, C.P. Strassburg, H. Wedemeyer, M.P. Manns, T. Pietschmann, and T. von Hahn Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles J. Virol. 85 2011 7613 7621
18. G. Crespo, Z. Marino, M. Navasa, and X. Forns Viral hepatitis in liver transplantation Gastroenterology 142 2012 1373e1 1383e1
19. L. Cukierman, L. Meertens, C. Bertaux, F. Kajumo, and T. Dragic Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts J. Virol. 83 2009 5477 5484
20. M.P. Curry, X. Forns, R.T. Chung, N. Terrault, R.S. Brown, J.M. Fenkel, F.D. Gordon, J.G. O'Leary, A. Kuo, T.D. Schiano, G.T. Everson, E.R. Schiff, A. Befeler, J.G. McHutchison, W.T. Symonds, J.M. Denning, L. McNair, S. Arterburn, D. Moonka, E.J. Gane, and N.H. Afdhal Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation 2013 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 3012) Washington [1-5, Abstract 213]
21. M. Deest, S. Westhaus, E. Steinmann, M.P. Manns, T. von Hahn, and S. Ciesek Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization Antiviral Res. 101 2014 37 44
22. J. Diao, H. Pantua, H. Ngu, L. Komuves, L. Diehl, G. Schaefer, and S.B. Kapadia Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry J. Virol. 86 2012 10935 10949
23. C.A. Didigu, and R.W. Doms Novel approaches to inhibit HIV entry Viruses 4 2012 309 324
24. M. Dorner, J.A. Horwitz, J.B. Robbins, W.T. Barry, Q. Feng, K. Mu, C.T. Jones, J.W. Schoggins, M.T. Catanese, D.R. Burton, M. Law, C.M. Rice, and A. Ploss A genetically humanized mouse model for hepatitis C virus infection Nature 474 2011 208 211
25. M. Dorner, J.A. Horwitz, B.M. Donovan, R.N. Labitt, W.C. Budell, T. Friling, A. Vogt, M.T. Catanese, T. Satoh, T. Kawai, S. Akira, M. Law, C.M. Rice, and A. Ploss Completion of the entire hepatitis C virus life cycle in genetically humanized mice Nature 501 2013 237 241
26. M.J. Evans, T. von Hahn, D.M. Tscherne, A.J. Syder, M. Panis, B. Wolk, T. Hatziioannou, J.A. McKeating, P.D. Bieniasz, and C.M. Rice Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801 805 (Pubitemid 46582027)
27. S. Fafi-Kremer, I. Fofana, E. Soulier, P. Carolla, P. Meuleman, G. Leroux-Roels, A.H. Patel, F.-L. Cosset, P. Pessaux, M. Doffoël, P. Wolf, F. Stoll-Keller, and T.F. Baumert Enhanced viral entry and escape from antibody-mediated neutralization are key determinants for hepatitis C virus re-infection in liver transplantation J. Exp. Med. 207 2010 2019 2031
28. M.J. Farquhar, H.J. Harris, and J.A. McKeating Hepatitis C virus entry and the tetraspanin CD81 Biochem. Soc. Trans. 39 2011 532 536
29. M.J. Farquhar, K. Hu, H.J. Harris, C. Davis, C.L. Brimacombe, S.J. Fletcher, T.F. Baumert, J.Z. Rappoport, P. Balfe, and J.A. McKeating Hepatitis C virus induces CD81 and claudin-1 endocytosis J. Virol. 86 2012 4305 4316
30. S.A. Fink, and I.M. Jacobson Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis Nat. Rev. Gastroenterol. Hepatol. 8 2011 285 295
31. I. Fofana, S.E. Krieger, F. Grunert, S. Glauben, F. Xiao, S. Fafi-Kremer, E. Soulier, C. Royer, C. Thumann, C.J. Mee, J.A. McKeating, T. Dragic, C. Schuster, J. Thompson, and T.F. Baumert Monoclonal anti-claudin 1 antibodies for prevention of hepatitis C virus infection Gastroenterology 139 953-964 2010 964e1 964e4
32. I. Fofana, S. Fafi-Kremer, P. Carolla, C. Fauvelle, M.N. Zahid, M. Turek, L. Heydmann, K. Cury, J. Hayer, C. Combet, F.L. Cosset, T. Pietschmann, M.S. Hiet, R. Bartenschlager, F. Habersetzer, M. Doffoel, Z.Y. Keck, S.K. Foung, M.B. Zeisel, F. Stoll-Keller, and T.F. Baumert Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies Gastroenterology 143 2012 223e9 233e9
33. I. Fofana, F. Xiao, C. Thumann, M. Turek, L. Zona, R.G. Tawar, F. Grunert, J. Thompson, M.B. Zeisel, and T.F. Baumert A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits hepatitis C virus cell-cell transmission PLoS ONE 8 2013 e64221
34. I. Fofana, L. Zona, C. Thumann, L. Heydmann, S.C. Durand, J. Lupberger, H.E. Blum, P. Pessaux, C. Gondeau, G.M. Reynolds, J.A. McKeating, F. Grunert, J. Thompson, M.B. Zeisel, and T.F. Baumert Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies J. Virol. 87 2013 10405 10410
35. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, R. Elston, D. Ipe, P.N. Morcos, L. Baher, I. Najera, T. Chu, U. Lopatin, M.M. Berrey, W. Bradford, M. Laughlin, N.S. Shulman, and P.F. Smith Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
36. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, W.T. Symonds, R.G. Hindes, and M.M. Berrey Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N. Engl. J. Med. 368 2013 34 44
37. E.J. Gane, E. Lawitz, M. Rodriguez-Torres, S.C. Gordon, H. Dvory-Sobol, S. Arterburn, J. McNally, D.M. Brainard, W.T. Symonds, J.G. McHutchison, A.M. Sheikh, and A. Mangia Phase 3 Randomized Controlled Trial of all-Oral Treatment with Sofosbuvir + Ribavirin for 12 weeks Compared to 24 weeks of Peg + Ribavirin in Treatment-Naive GT2/3 HCV-Infected Patients (FISSION) 2013 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) Amsterdam [24-28, Abstract 5]
38. E. Giang, M. Dorner, J.C. Prentoe, M. Dreux, M.J. Evans, J. Bukh, C.M. Rice, A. Ploss, D.R. Burton, and M. Law Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Proc. Natl. Acad. Sci. USA 109 2012 6205 6210
39. S. Haid, A. Novodomska, J. Gentzsch, C. Grethe, S. Geuenich, D. Bankwitz, P. Chhatwal, B. Jannack, T. Hennebelle, F. Bailleul, O.T. Keppler, M. Poenisch, R. Bartenschlager, C. Hernandez, M. Lemasson, A.R. Rosenberg, F. Wong-Staal, E. Davioud-Charvet, and T. Pietschmann A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes Gastroenterology 143 2012 213e5 222e5
40. S. Haid, C. Grethe, M.T. Dill, M. Heim, L. Kaderali, and T. Pietschmann Isolate-dependent use of Claudins for cell entry by hepatitis C virus Hepatology 59 2014 24 34
41. H.J. Harris, C. Davis, J.G. Mullins, K. Hu, M. Goodall, M.J. Farquhar, C.J. Mee, K. McCaffrey, S. Young, H. Drummer, P. Balfe, and J.A. McKeating Claudin association with CD81 defines hepatitis C virus entry J. Biol. Chem. 285 2010 21092 21102
42. M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat. Rev. Immunol. 13 2013 535 542
43. T.J. Henrich, and D.R. Kuritzkes HIV-1 entry inhibitors: recent development and clinical use Curr. Opin. Virol. 3 2013 51 57
44. M. Hsu, J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C.M. Rice, and J.A. McKeating Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles Proc. Natl. Acad. Sci. USA 100 2003 7271 7276 (Pubitemid 36706428)
45. M. Hsu, J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C.M. Rice, and J.A. McKeating Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles Proc. Natl. Acad. Sci. USA 100 2003 7271 7276 (Pubitemid 36706428)
46. G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig, K. Allers, T. Schneider, J. Hofmann, C. Kucherer, O. Blau, W. BlauI, W.K. Hofmann, and E. Thiel Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N. Engl. J. Med. 360 2009 692 698
47. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, and S. Zeuzem Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
48. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, M.L. Shiffman, E. Lawitz, G. Everson, M. Bennett, E. Schiff, M.T. Al-Assi, G.M. Subramanian, D. An, M. Lin, J. McNally, D. Brainard, W.T. Symonds, J.G. McHutchison, K. Patel, J. Feld, S. Pianko, and D.R. Nelson Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N. Engl. J. Med. 368 2013 1867
49. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, M. Demicco, D.E. Bernstein, N. Afdhal, J.M. Vierling, S.C. Gordon, J.K. Anderson, R.H. Hyland, H. Dvory-Sobol, D. An, R.G. Hindes, E. Albanis, W.T. Symonds, M.M. Berrey, D.R. Nelson, and I.M. Jacobson Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
50. S.E. Krieger, M.B. Zeisel, C. Davis, C. Thumann, H.J. Harris, E.K. Schnober, C. Mee, E. Soulier, C. Royer, M. Lambotin, F. Grunert, V.L. Dao Thi, M. Dreux, F.L. Cosset, J.A. McKeating, C. Schuster, and T.F. Baumert Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations Hepatology 51 2010 1144 1157
51. K. Lacek, K. Vercauteren, K. Grzyb, M. Naddeo, L. Verhoye, M.P. Slowikowski, S. Fafi-Kremer, A.H. Patel, T.F. Baumert, A. Folgori, G. Leroux-Roels, R. Cortese, P. Meuleman, and A. Nicosia Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice J. Hepatol. 57 2012 17 23
52. M. Lavie, C. Voisset, N. Vu-Dac, V. Zurawski, G. Duverlie, C. Wychowski, and J. Dubuisson Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system Hepatology 44 2006 1626 1634 (Pubitemid 44953668)
53. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, A.M. Sheikh, N.H. Afdhal, D.E. Bernstein, E. Dejesus, B. Freilich, D.R. Nelson, D.T. Dieterich, I.M. Jacobson, D. Jensen, G.A. Abrams, J.M. Darling, M. Rodriguez-Torres, K.R. Reddy, M.S. Sulkowski, N.H. Bzowej, R.H. Hyland, H. Mo, M. Lin, M. Mader, R. Hindes, E. Albanis, W.T. Symonds, M.M. Berrey, and A. Muir Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect. Dis. 13 2013 401 408
54. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, M. Schultz, M.N. Davis, Z. Kayali, K.R. Reddy, I.M. Jacobson, K.V. Kowdley, L. Nyberg, G.M. Subramanian, R.H. Hyland, S. Arterburn, D. Jiang, J. McNally, D. Brainard, W.T. Symonds, J.G. McHutchison, A.M. Sheikh, Z. Younossi, and E.J. Gane Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 368 2013 1878 1887
55. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, H. Mo, W.T. Symonds, J.G. McHutchison, and F.E. Membreno Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 583 2014 515 523
56. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N. Engl. J. Med. 368 2013 1907 1917
57. B.D. Lindenbach, M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, and C.M. Rice Complete replication of hepatitis C virus in cell culture Science 309 2005 623 626 (Pubitemid 41033648)
58. V. Lohmann, F. Körner, J.O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113 (Pubitemid 29307577)
59. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, M. Wind-Rotolo, A. Persson, K. Zhu, D.I. Dimitrova, T. Eley, T. Guo, D.M. Grasela, and C. Pasquinelli Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 366 2012 216 224
60. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, L. Zona, C. Davis, C.J. Mee, M. Turek, S. Gorke, C.B.F. Royer, M.N. Zahid, D.J.F. Lavillette, F.-L. Cosset, S.M. Rothenberg, T. Pietschmann, A.H. Patel, P. Pessaux, M. Doffoël, W. Raffelsberger, O. Poch, J.A. McKeating, L. Brino, and T.F. Baumert EGFR and EphA2 are hepatitis C virus host entry factors and targets for antiviral therapy Nat. Med. 17 2011 589 595
61. M.P. Manns, E. Gane, M. Rodriguez-Torres, A. Stoehr, C.T. Yeh, P. Marcellin, R.T. Wiedmann, P.M. Hwang, L. Caro, R.J. Barnard, and A.W. Lee Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study Hepatology 56 2012 884 893
62. Z. Marino, G. Crespo, M. D'Amato, N. Brambilla, G. Giacovelli, L. Rovati, J. Costa, M. Navasa, and X. Forns Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period J. Hepatol. 58 2013 415 420
63. D.N. Martin, and S.L. Uprichard Identification of transferrin receptor 1 as a hepatitis C virus entry factor Proc. Natl. Acad. Sci. USA 110 2013 10777 10782
64. T. Matsumura, Z. Hu, T. Kato, M. Dreux, Y.Y. Zhang, M. Imamura, N. Hiraga, J.M. Juteau, F.L. Cosset, K. Chayama, A. Vaillant, and T.J. Liang Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry Gastroenterology 137 2009 673 681
65. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, N.H. Afdhal, E.J. Heathcote, S. Zeuzem, H.W. Reesink, J. Garg, M. Bsharat, S. George, R.S. Kauffman, N. Adda, and A.M. Di Bisceglie Telaprevir for previously treated chronic HCV infection N. Engl. J. Med. 362 2010 1292 1303
66. L. Meertens, C. Bertaux, L. Cukierman, E. Cormier, D. Lavillette, F.L. Cosset, and T. Dragic The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus J. Virol. 82 2008 3555 3560 (Pubitemid 351429931)
67. D.F. Mercer, D.E. Schiller, J.F. Elliott, D.N. Douglas, C. Hao, A. Rinfret, W.R. Addison, K.P. Fischer, T.A. Churchill, J.R. Lakey, D.L. Tyrrell, and N.M. Kneteman Hepatitis C virus replication in mice with chimeric human livers Nat. Med. 7 2001 927 933 (Pubitemid 32756430)
68. P. Meuleman, J. Hesselgesser, M. Paulson, T. Vanwolleghem, I. Desombere, H. Reiser, and G. Leroux-Roels Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo Hepatology 48 2008 1761 1768
69. P. Meuleman, M.T. Catanese, L. Verhoye, I. Desombere, A. Farhoudi, C.T. Jones, T. Sheahan, K. Grzyb, R. Cortese, C.M. Rice, G. Leroux-Roels, and A. Nicosia A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo Hepatology 55 2012 364 372
70. C. Nathan Fresh approaches to anti-infective therapies Sci. Transl. Med. 4 2012 140sr2
71. A. Osinusi, E.G. Meissner, Y.J. Lee, D. Bon, L. Heytens, A. Nelson, M. Sneller, A. Kohli, L. Barrett, M. Proschan, E. Herrmann, B. Shivakumar, W. Gu, R. Kwan, G. Teferi, R. Talwani, R. Silk, C. Kotb, S. Wroblewski, D. Fishbein, R. Dewar, H. Highbarger, X. Zhang, D. Kleiner, B.J. Wood, J. Chavez, W.T. Symonds, M. Subramanian, J. McHutchison, M.A. Polis, A.S. Fauci, H. Masur, and S. Kottilil Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
72. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
73. J.M. Pawlotsky Treatment of chronic hepatitis C: current and future Curr. Top. Microbiol. Immunol. 369 2013 321 342
74. P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A.J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani Binding of hepatitis C virus to CD81 Science 282 1998 938 941 (Pubitemid 28507525)
75. A. Ploss, and M.J. Evans Hepatitis C virus host cell entry Curr. Opin. Virol. 2 2012 14 19
76. A. Ploss, M.J. Evans, V.A. Gaysinskaya, M. Panis, H. You, Y.P. de Jong, and C.M. Rice Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Nature 457 2009 882 886
77. P.J. Pockros, D. Jensen, N. Tsai, R. Taylor, A. Ramji, C. Cooper, R. Dickson, A. Tice, R. Kulkarni, J.M. Vierling, M. Lou Munson, Y.C. Chen, I. Najera, and J. Thommes JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients Hepatology 58 2013 514 523
78. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, N. Boparai, M.J. DiNubile, V. Sniukiene, C.A. Brass, J.K. Albrecht, and J.P. Bronowicki Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1195 1206
79. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, S. Siggelkow, M. Heckaman, L. Larsen, R. Menon, G. Koev, R. Tripathi, T. Pilot-Matias, and B. Bernstein Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 368 2013 45 53
80. J. Prentoe, T.B. Jensen, P. Meuleman, S.B. Serre, T.K. Scheel, G. Leroux-Roels, J.M. Gottwein, and J. Bukh Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization J. Virol. 85 2011 2224 2234
81. G.M. Reynolds, H.J. Harris, A. Jennings, K. Hu, J. Grove, P.F. Lalor, D.H. Adams, P. Balfe, S.G. Hubscher, and J.A. McKeating Hepatitis C virus receptor expression in normal and diseased liver tissue Hepatology 47 2008 418 427 (Pubitemid 351280709)
82. M. Saag, J. Goodrich, G. Fatkenheuer, B. Clotet, N. Clumeck, J. Sullivan, M. Westby, E. van der Ryst, and H. Mayer A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1 J. Infect. Dis. 199 2009 1638 1647
83. B. Sainz Jr., N. Barretto, D.N. Martin, N. Hiraga, M. Imamura, S. Hussain, K.A. Marsh, X. Yu, K. Chayama, W.A. Alrefai, and S.L. Uprichard Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor Nat. Med. 18 2012 281 285
84. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
85. C. Sarrazin, C. Hezode, S. Zeuzem, and J.M. Pawlotsky Antiviral strategies in hepatitis C virus infection J. Hepatol. 56 Suppl. 1 2012 S88 S100
86. E. Scarselli, H. Ansuini, R. Cerino, R.M. Roccasecca, S. Acali, G. Filocamo, C. Traboni, A. Nicosia, R. Cortese, and A. Vitelli The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus EMBO J. 21 2002 5017 5025
87. R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah HCV direct-acting antiviral agents: the best interferon-free combinations Liver Int. 34 Suppl. 1 2014 69 78
88. C.J. Schweitzer, and T.J. Liang Impact of host and virus genome variability on HCV replication and response to interferon Curr. Opin. Virol. 3 2013 501 507
89. A.K. Sharma, V. George, R. Valiathan, S.P. Kanthikeel, and S. Pallikkuth Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment Recent Pat. Inflamm. Allergy Drug Discov. 7 2013 151 161
90. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, and L. Seymour Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 2005 123 132 (Pubitemid 41058344)
91. V. Soriano, E. Vispo, E. Poveda, P. Labarga, and P. Barreiro Treatment failure with new hepatitis C drugs Expert Opin. Pharmacother. 13 2012 313 323
92. M.S. Sulkowski, T. Asselah, J. Lalezari, P. Ferenci, H. Fainboim, B. Leggett, F. Bessone, S. Mauss, J. Heo, Y. Datsenko, J.O. Stern, G. Kukolj, J. Scherer, G. Nehmiz, G.G. Steinmann, and W.O. Bocher Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
93. M.S. Sulkowski, M. Bourliere, J.P. Bronowicki, T. Asselah, J.M. Pawlotsky, S.D. Shafran, S. Pol, S. Mauss, D. Larrey, Y. Datsenko, J.O. Stern, G. Kukolj, J. Scherer, G. Nehmiz, G.G. Steinmann, and W.O. Bocher Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial Hepatology 57 2013 2155 2163
94. M.S. Sulkowski, M. Kang, R. Matining, D. Wyles, V.A. Johnson, G.D. Morse, V. Amorosa, D. Bhattacharya, K. Coughlin, F. Wong-Staal, and M.J. Glesby Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study J. Infect. Dis. 209 2014 658 667
95. A.J. Syder, H. Lee, M.B. Zeisel, J. Grove, E. Soulier, J. Macdonald, S. Chow, J. Chang, T.F. Baumert, J.A. McKeating, J. McKelvy, and F. Wong-Staal Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors J. Hepatol. 54 2011 48 55
96. A.W. Tarr, P. Lafaye, L. Meredith, L. Damier-Piolle, R.A. Urbanowicz, A. Meola, J.L. Jestin, R.J. Brown, J.A. McKeating, F.A. Rey, J.K. Ball, and T. Krey An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission Hepatology 58 2013 932 939
97. J.M. Timpe, Z. Stamataki, A. Jennings, K. Hu, M.J. Farquhar, H.J. Harris, A. Schwarz, I. Desombere, G.L. Roels, P. Balfe, and J.A. McKeating Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies Hepatology 47 2008 17 24 (Pubitemid 351171037)
98. X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, V. Baronas, J.M. Yan, S.S. So, K. Klumpp, and I. Najera In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir J. Infect. Dis. 209 2014 668 675
99. D.M. Tscherne, C.T. Jones, M.J. Evans, B.D. Lindenbach, J.A. McKeating, and C.M. Rice Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry J. Virol. 80 2006 1734 1741 (Pubitemid 43228714)
100. S.E. VanCompernolle, A.V. Wiznycia, J.R. Rush, M. Dhanasekaran, P.W. Baures, and S.C. Todd Small molecule inhibition of hepatitis C virus E2 binding to CD81 Virology 314 2003 371 380 (Pubitemid 37158015)
101. T. Volz, L. Allweiss, M.B. MB, M. Warlich, A.W. Lohse, J.M. Pollok, A. Alexandrov, S. Urban, J. Petersen, M. Lutgehetmann, and M. Dandri The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus J. Hepatol. 58 2013 861 867
102. T. von Hahn, S. Ciesek, and M.P. Manns Arrest all accessories - inhibition of hepatitis C virus by compounds that target host factors Discov. Med. 12 2011 237 244
103. J. Wagoner, A. Negash, O.J. Kane, L.E. Martinez, Y. Nahmias, N. Bourne, D.M. Owen, J. Grove, C. Brimacombe, J.A. McKeating, E.I. Pecheur, T.N. Graf, N.H. Oberlies, V. Lohmann, F. Cao, J.E. Tavis, and S.J. Polyak Multiple effects of silymarin on the hepatitis C virus lifecycle Hepatology 51 2010 1912 1921
104. T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, and T.J. Liang Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat. Med. 11 2005 791 796 (Pubitemid 41021213)
105. J. Witteveldt, M.J. Evans, J. Bitzegeio, G. Koutsoudakis, A.M. Owsianka, A.G. Angus, Z.Y. Keck, S.K. Foung, T. Pietschmann, C.M. Rice, and A.H. Patel CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells J. Gen. Virol. 90 2009 48 58
106. M.N. Zahid, M. Turek, F. Xiao, V.L. Dao Thi, M. Guerin, I. Fofana, P. Bachellier, J. Thompson, L. Delang, J. Neyts, D. Bankwitz, T. Pietschmann, M. Dreux, F.L. Cosset, F. Grunert, T.F. Baumert, and M.B. Zeisel The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination Hepatology 57 2013 492 504
107. M.B. Zeisel, I. Fofana, S. Fafi-Kremer, and T.F. Baumert Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies J. Hepatol. 54 2011 566 576
108. M.B. Zeisel, D.J. Felmlee, and T.F. Baumert Hepatitis C virus entry Curr. Top. Microbiol. Immunol. 369 2013 87 112
109. M.B. Zeisel, J. Lupberger, I. Fofana, and T.F. Baumert Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges J. Hepatol. 58 2013 375 384
110. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, A.W. Lohse, B. Mullhaupt, M. Schuchmann, M. Bourliere, M. Buti, S.K. Roberts, E.J. Gane, J.O. Stern, R. Vinisko, G. Kukolj, J.P. Gallivan, W.O. Bocher, and F.J. Mensa Faldaprevir and deleobuvir for HCV genotype 1 infection N. Engl. J. Med. 369 2013 630 639
111. S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, M.W. Fried, C. Hezode, G.M. Hirschfield, I. Jacobson, I. Nikitin, P.J. Pockros, F. Poordad, J. Scott, O. Lenz, M. Peeters, V. Sekar, G. De Smedt, R. Sinha, and M. Beumont-Mauviel Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 2013 [Epub ahead of print]
112. A. Zheng, F. Yuan, Y. Li, F. Zhu, P. Hou, J. Li, X. Song, M. Ding, and H. Deng Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus J. Virol. 81 2007 12465 12471
113. J. Zhong, P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D.R. Burton, S.F. Wieland, S.L. Uprichard, T. Wakita, and F.V. Chisari Robust hepatitis C virus infection in vitro Proc. Natl. Acad. Sci. USA 102 2005 9294 9299 (Pubitemid 40923557)
114. H. Zhu, F. Wong-Staal, H. Lee, A. Syder, J. McKelvy, R.T. Schooley, and D.L. Wyles Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals J. Infect. Dis. 205 2012 656 662
115. L. Zona, J. Lupberger, N. Sidahmed-Adrar, C. Thumann, H.J. Harris, A. Barnes, J. Florentin, R.G. Tawar, F. Xiao, M. Turek, S.C. Durand, F.H. Duong, M.H. Heim, F.L. Cosset, I. Hirsch, D. Samuel, L. Brino, M.B. Zeisel, F. Le Naour, J.A. McKeating, and T.F. Baumert HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex Cell Host Microbe 13 2013 302 313